Zeteo Tech Awarded $1.87M DHS Science & Technology Directorate Contract to Develop and Test the Next Generation of the digitalMALDI® Real-Time Biological Threat Detection Technology

We are excited to share that the U.S. Department of Homeland Security has awarded Zeteo Tech a Phase III Small Business Innovation Research contract for $1.87M, with a potential value of up to $5.86 million. This new contract will fund the development and testing of digitalMALDI®, our next generation of sensor technology that enables real-time detection of aerosolized biological-threat agents that include bacteria, viruses, and toxins.

 

We look forward to assisting the DHS Science and Technology Directorate with its ongoing efforts to develop new tools for improving detection and response times to potential bioterrorism attacks or naturally occurring biological incidents. 

 

 

Read more in the press release here: https://www.businesswire.com/news/home/20231212977930/en/Zeteo-Tech-Awarded-1.87M-DHS-Science-Technology-Directorate-Contract-to-Develop-and-Test-the-Next-Generation-of-the-digitalMALDI%C2%AE-Real-Time-Biological-Threat-Detection-Technology

 

Zeteo Tech Expands IP Portfolio of Mass Spectrometry Technology

SYKESVILLE, Md.–(BUSINESS WIRE)–Zeteo Tech, Inc., the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers and innovative human breath detection technologies, announced today the issuance of U.S. Patent No. 11658021, titled “Systems and Methods of Rapid and Autonomous Detection of Aerosol Particles.”

Using the patented “point-of-need” portable threat detection system, air samples can be automatically collected and analyzed for chemical and biological aerosolized threat agents, including bacteria, viruses, toxins, and chemicals such as fentanyl. The system’s sophisticated microfluidics, control architecture, threat agent library, and AI/ML software enable threat identification with high specificity and sensitivity within just a few minutes.

“This latest patent adds to Zeteo Tech’s robust IP portfolio protecting our technology that can perform rapid analysis of biological aerosols, including bacteria, viruses, and toxins,” said Dr. Wayne Bryden, President and CEO of Zeteo Tech. “Our mission is to collaborate with partners to commercialize our technology in order to help protect life and critical infrastructure by enabling rapid detection and accelerated initiation of emergency management protocols. For example, the system is capable of rapidly detecting new biological threats and being deployed in potential pandemic scenarios, similar to COVID-19.”

This patent marks the fourth U.S. Patent for Zeteo Tech on mass spectrometry technology, (3 granted and 1 allowed). In addition, Zeteo Tech has 12 mass spectrometry related foreign patents, (11 granted and 1 allowed).

Zeteo Tech has licensed its portable threat detection technology to Albuquerque-based bioaerosol surveillance company, BioFlyte. This agreement allows BioFlyte to use the technology for environmental sampling, detection, monitoring, and identification of chemical and biological threats within the defense and security market. BioFlyte is partnering with financial institutions, government organizations, like the Department of Defense, and airports, such as the Pittsburgh International Airport, to test and demonstrate the capabilities of its BioTOF™ z200 system.

“BioFlyte emerged from Zeteo Tech’s impressive portfolio of proprietary mass spectrometry technology, and our ongoing strategic partnership has been critical for our growth,” said BioFlyte CEO Todd Sickles. “With Zeteo’s support, BioFlyte is commercializing this groundbreaking rapid threat detection technology to protect people, critical infrastructure, and more.”

To learn more about Zeteo Tech and its technology, please visit www.zeteotech.com.

About Zeteo Tech
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Zeteo’s instruments identify airborne microbes, proteins, and lipids, and can be used to screen for infectious disease and other biothreats. Its innovative, patented and patent-pending time of flight mass spectrometry technology, digitalMALDI®, enables fully automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems being currently deployed for biodefense applications. To learn more, visit www.zeteotech.com.

Contacts

Media
Brandon Reid for Zeteo Tech
bwr@anzupartners.com

 

https://www.businesswire.com/news/home/20231114380747/en/Zeteo-Tech-Expands-IP-Portfolio-of-Mass-Spectrometry-Technology

Zeteo Tech Awarded Competitive Grant From the National Institute of Allergy and Infectious Diseases

Small Business Innovation Research Program provides seed funding to fuel R&D for Zeteo
Tech’s Innovative Approach for Detecting Disease Markers in Human Breath.

Zeteo Tech, Inc. the biodefense and medical device company that has developed a
revolutionary new class of fieldable biological mass spectrometers and innovative human breath
detection technologies, has been awarded a National Institute Of Allergy And Infectious
Diseases (NIAID) Direct to Phase II Small Business Innovation Research (SBIR) grant for
$967,498, for the first year of a two year effort, totaling $1.9M, on “Noninvasive Diagnostic
Markers of Lower Respiratory Tract Infection in Mechanically Ventilated Patients”. Dr. Dapeng
Chen of Zeteo Tech, Inc. is the Principal Investigator for this grant.

The potential for human breath to serve as a non-invasive diagnostic tool has garnered
significant attention from healthcare professionals and industry experts alike. Lower respiratory
tract infections (LRTIs) are a common concern for ICU patients, particularly those with
mechanical ventilators. Zeteo Tech, Inc., in collaboration with the Johns Hopkins Hospital, will
investigate whether truncated proteoforms in human exhaled air can serve as a non-invasive
diagnostic marker for LRTIs, and early prediction of LRTI in mechanically ventilated patients. If
successful, this breakthrough research will provide clinicians with a valuable tool for decision-making
regarding antibiotic treatment, resulting in improved patient outcomes and reduced exposure to harmful
antibiotic treatments.

“We are absolutely delighted to win this highly competitive award from NIAID for our research
directed toward breath-based detection and characterization of LRTI. Dr. Chen, his team at
Zeteo Tech, and collaborators from Johns Hopkins developed highly convincing evidence for
this approach, leading to this NIAID award, and we are pleased to now add ASELL, LLC to the
team to support our commercialization efforts. This work is a critical component in Zeteo Tech’s
drive to transition technology investments by the Department of Defense and Department of
Homeland Security into medical tools that will revolutionize the diagnosis and treatment of lung
infections. Beyond LRTI, we expect these tools to evolve into platforms for point-of-care
diagnosis and assessment of multiple disease states and conditions.” said Wayne Bryden,
President and CEO of Zeteo Tech, Inc.

The work in this press release is supported by the National Institute Of Allergy And Infectious Diseases of the
National Institutes of Health under Award Number R44AI177245. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the National Institutes of Health

Zeteo Tech Awarded Competitive Grant From the National Science Foundation

SYKESVILLE, Md.–(BUSINESS WIRE)–Zeteo Tech, the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers, has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $256,000. The grant will be leveraged for research and development on its COVID-19 Fully Automated Disinfection System (CFADS) to help rapidly return aircraft and subway cars safely to service and disinfect public gathering spaces.

https://www.businesswire.com/news/home/20210817005218/en/Zeteo-Tech-Awarded-Competitive-Grant-From-the-National-Science-Foundation

Zeteo Tech Appoints Former U.S. Assistant Secretary of Defense Andrew Weber to Board of Directors

SYKESVILLE, Md., July 29, 2020 /PRNewswire/ — Zeteo Tech, the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers, today announced that the Honorable Andrew Weber has joined its Board of Directors. Mr. Weber served as the Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs under President Obama.

“Andy has dedicated much of his professional career working to strengthen our Nation’s security and response to nuclear, chemical, and biological threats,” said Wayne Bryden, PhD, President and CEO of Zeteo Tech. “We are delighted that he is joining the Board, and his unmatched wealth of knowledge and experience will be greatly utilized as Zeteo continues to grow its commercial and government offerings.”

Zeteo Tech’s proprietary digitalMALDI® technology pushes mass spectrometry innovation to a new level of sensitivity and specificity, enabling its instruments to obtain biomarker measurements from individual particles in the bioaerosol and then complete a biomarker-specific molecular identification in seconds. A combination of proprietary bioaerosol processing and MALDI mass spectrometry enables the technology’s ground-breaking advances to eliminate environmental background. By discretizing the sample in time, the analysis is exceptionally fast, sensitive and specific.

In addition to Mr. Weber’s public service as the Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, he was a driving force behind Nunn-Lugar Cooperative Threat Reduction efforts to remove weapons-grade uranium from Kazakhstan and Georgia and nuclear-capable MiG-29 aircraft from Moldova, to reduce biological weapons threats, and to destroy Libyan and Syrian chemical weapons stockpiles. Mr. Weber also coordinated leadership of the international Ebola response for the U.S. Department of State.

Prior to joining the Pentagon as Advisor for Threat Reduction Policy in December 1996, Mr. Weber was posted abroad as a U.S. Foreign Service Officer in Saudi Arabia, Germany, Kazakhstan, and Hong Kong. Mr. Weber is an independent consultant and a Strategic Advisor for Ginkgo BioWorks. He serves on the Boards of Healthcare Ready and the Arms Control Association, and the James Martin Center for Non-proliferation Studies International Advisory Council.

Mr. Weber taught at the Georgetown University Graduate School of Foreign Service for seven years and was a Senior Fellow at the Harvard Kennedy School’s Belfer Center for Science and International Affairs. Mr. Weber graduated from Cornell University and holds a Master of Science in Foreign Service (MSFS) degree from Georgetown University. He is a member of the Council on Foreign Relations and a Senior Fellow at the Council on Strategic Risks, a non-partisan, non-profit think tank working against existential threats.

For more information about Zeteo Tech, please visit https://zeteotech1.wpengine.com.

About Zeteo Tech
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Its instruments identify airborne microbes, proteins and lipids, and can be used to screen for infectious disease and other bio-threats. Its innovative and patent-pending time of flight mass spectrometry technology, digitalMALDI®, enables fully-automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems being launched for biodefense applications.

CONTACT
Rob Haralson for Zeteo Tech
rhh@anzupartners.com, (202) 674-6679

Zeteo Tech Awarded $6.5M DHS S&T Contract to Develop and Test digitalMALDI™ Real-Time Biological Threat Detection Technology

Sykesville, Md., April 15, 2019 /PRNewswire/ — Zeteo Tech, the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers, today announced that it has been awarded a contract of up to $6.5 million (including options) from the U.S. Department of Homeland Security (DHS) to develop and test a new sensor technology that enables real-time detection of aerosolized biological threat agents including bacteria, viruses, and toxins. The contract was awarded in support of the Department’s Science and Technology Directorate (S&T).

“We are excited to have been selected for this award to assist the U.S. Department of Homeland Security with its ongoing efforts to improve detection and response times to potential bioterrorism attacks or naturally occurring biological incidents,” said Dr. Wayne Bryden, President and CEO of Zeteo Tech. “Our team’s deep expertise with developing fieldable and real-time biological mass spectrometers is perfectly aligned to help DHS achieve its objective of protecting citizens and critical infrastructures from biological threats.”

DHS S&T is working to develop, test, and deploy new technologies that will decrease the time required to detect a biological incident. Current systems can require up to 12-36 hours to detect an aerosolized biological threat agent and are costly to operate. The sensor to be developed under this program is intended to contain component technologies that would have both trigger and detector functions, and improve current capabilities by:

  • Reducing the amount of time required to detect the presence of a biological threat following release from the current 12-36 hour timeframe down to minutes
  • Increasing the total number of biological threats that can be detected over current technologies
  • Significantly lowering deployment, operations, and maintenance costs on a per sensor basis

“By combining both trigger and detector technologies, the sensor we are developing offers the potential for continuous air monitoring with the ability to rapidly and accurately identify biological particles indicative of a bioterrorist event,” said Mike McLoughlin, VP of Research at Zeteo Tech.

For more information about Zeteo Tech, please visit https://zeteotech1.wpengine.com.

###

About Zeteo Tech

Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Its instruments identify airborne microbes, proteins and lipids, and can be used to screen for infectious disease and other bio-threats. Its innovative and patent-pending time of flight mass spectrometry technology, digitalMALDI®, enables fully-automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems currently deployed for biodefense applications.

Zeteo Tech is backed by venture capital firm Anzu Partners, which invests in breakthrough industrial technologies.

Zeteo Tech Raises $3.5M in Series A Funding Round

SYKESVILLE, Md., April 15, 2019 /PRNewswire/ — Zeteo Tech, the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers, today announced that it has raised $3.5 million in seed stage funding from industrial technology venture capital firm Anzu Partners. The funding will be used for the continued development of its digitalMALDI® technology and the commercialization of its biological mass spectrometers used to identify airborne infectious disease and bio-terror threats.

“Zeteo Tech’s mass spectrometry systems enable fully-automated and near real-time identification of bio-threats in operational environments, said Dr. Wayne Bryden, President and CEO of Zeteo Tech. “This infusion of capital from Anzu Partners will help us accelerate our commercialization timeline to ensure our compact, low-power instruments can be deployed to the applications and geographical regions that need it the most.”

Zeteo Tech’s digitalMALDI® technology pushes the innovation to a whole new level of sensitivity and specificity, enabling its instruments to obtain biomarker measurements from individual particles in the bioaerosol and then complete a biomarker-specific molecular identification in seconds A combination of proprietary bioaerosol processing and MALDI mass spectrometry enables the technology’s ground-breaking advances to eliminate environmental background. By discretizing the sample in time, the analysis is exceptionally fast, sensitive and specific.

For more information about Zeteo Tech, please visit https://zeteotech1.wpengine.com.

About Zeteo Tech
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Its instruments identify airborne microbes, proteins and lipids, and can be used to screen for infectious disease and other bio-threats. Its innovative and patent-pending time of flight mass spectrometry technology, digitalMALDI®, enables fully-automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems being launched for biodefense applications.

About Anzu Partners
Anzu Partners is a venture capital and private equity firm that invests in breakthrough industrial technologies. Anzu teams with entrepreneurs to develop and commercialize technological innovations by providing capital and deep expertise in business development, market positioning, global connectivity, and operations. For more information, please visit https://anzupartners.com. On Twitter: @anzupartners.